CTSA INFRASTRUCTURE FOR CLINICAL TRIALS AND PEDIATRIC RESEARCH

本分项目是CTSA供资的估计百分比，即 被用于广泛的研究领域(艾滋病研究、儿科研究或 临床试验)。列出的总成本仅是对CTSA金额的估计 用于这一研究领域的基础设施，而不是由 授予子项目或子项目工作人员的NCRR补助金。 临床和转化研究奖(CTSA)受到宾夕法尼亚大学(Penn)的热烈欢迎，一项战略计划将临床和转化研究确定为优先事项，导致转化医学和治疗研究所(ITMAT)于1月成立 2005年。ITMAT预计CTSA的一些方面-包括GCRC，专门用于翻译研究的“干”和“湿板凳”空间，以及一个强大的教育项目，配置在翻译研究硕士(MTR)上。CTSA的这一提议促使机构内部和机构间考虑如何在这一成就的基础上再接再厉。这在宾夕法尼亚大学、费城儿童医院(CHOP)、维斯塔尔研究所(WL)和费城科学大学(USP)之间建立了一个变革性的联盟。宾夕法尼亚大学12所学校中的9所学校和伙伴机构的教职员工在应对这项CTSA时发挥了领导作用。ITMAT被指定为临床和转化性研究的“学术之家”，现已扩大到服务于跨机构的角色。它的结构已经转变，以促进跨学科科学的发展，从发现新分子到研究大人口中的药物作用。这是通过发展跨学科中心、相关核心、创新的跨学科研究计划和战略来实现的，以吸引和告知社区及其医生。特别强调培训和创新方案，这些方案涵盖整个职业生涯，引人入胜 本科生到成熟的临床医生，都是建议的。这些措施包括灵活使用MTR和临床流行病学硕士(MSCE)中具有MD、PhD、VMD、MSN、DMD和MBA学位的新途径；为攻读MD-MTR/MSCE学位的医学院新生预留名额；灵活使用我们在宾夕法尼亚大学和CHOP的不同教师途径，以扩大医生在 研究。这些举措将与业界(例如葛兰素史克、甲骨文)、宾夕法尼亚州(BioAdvance)、FDA和持有CTSA的全国机构网络合作进行。已经制定了一种详细和多样化的方法来跟踪该计划的生产率，并将与类似的中心一起纳入国家计划。总而言之，这一倡议促进了(I)宾夕法尼亚大学、CHOP、WL和USP对临床和转化研究的综合战略，以及(Ii)ITMAT的转变。这将允许开发 设计了跨学科结构，以促进和促进这一新兴学科的研究和教育。

This subproject represents an estimate of the percentage of the CTSA funding that is being utilized for a broad area of research (AIDS research, pediatric research, or clinical trials). The Total Cost listed is only an estimate of the amount of CTSA infrastructure going towards this area of research, not direct funding provided by the NCRR grant to the subproject or subproject staff. The Clinical and Translational Research Award (CTSA) has been greeted enthusiastically by the University of Pennsylvania (Penn), A strategic plan had identified clinical and translational research as a priority, leading to formation of the Institute for Translational Medicine and Therapeutics (ITMAT) in January 2005. ITMAT anticipated some aspects of the CTSA - inclusion of the GCRC, dedicated "dry" and "wet bench" space for translational research and a robust educational program, configured on a Masters in Translational Research (MTR). This CTSA proposal prompted intra and inter-institutional consideration of how to build on this achievement. This has forged a transformational alliance between Penn, the Children's Hospital of Philadelphia (CHOP), the Wistar Institute (Wl) and the University of the Sciences in Philadelphia (USP). Faculty from 9 of the 12 schools at Penn and from the partner institutions are represented in leadership roles in the response to this CTSA. ITMAT, designated as the "academic home" for clinical and translational research, has been broadened to serve a trans-institutional role. Its structure has been transformed to foster interdisciplinary science from discovery of new molecules through to the study of drug action in large populations. This has been accomplished by developing interdisciplinary centers, related cores, innovative interdisciplinary programs of research and strategies to engage and inform communities and their physicians. A particular emphasis has been placed on training and innovative programs, which cover the entire career span, engaging undergraduate students through to mature clinicians, are proposed. These include the flexible use of the MTR and new tracks in the Masters in Clinical Epidemiology (MSCE) with the MD, PhD, VMD, MSN, DMD and MBA degrees; the set aside of places for medical school entrants pursuing MD-MTR/MSCE degrees and the flexible use of our diverse faculty tracks at Penn and CHOP to broaden physician engagement in research. These initiatives will be pursued in partnership with industry (e.g. GSK, Oracle), the State of Pennsylvania (BioAdvance), the FDA and a national network of institutions holding CTSAs. An elaborate and diversified approach to tracking the productivity of this program has been developed and will be integrated into a national plan with similar centers. In summary, this initiative has fostered (i) an integrated strategy to clinical and translational research by Penn, CHOP, the Wl and USP and (ii) the transformation of ITMAT. This will permit the development of interdisciplinary structures designed, to foster and facilitate research and education in this emerging discipline.